Hanmi présente le poster de l’essai en cours sur le BH3120 à la Society for Immunotherapy of Cancer (SITC) aux États-Unis. L’essai de phase 1 progresse sans problème, aucune toxicité limitant la dose n’ayant été observée L’essai de phase 1 évaluant la combinaison du BH3120 et de la…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.